PMID- 21752100
OWN - NLM
STAT- MEDLINE
DCOM- 20111227
LR  - 20191210
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 87
IP  - 6
DP  - 2011 Dec
TI  - BCL3 rearrangement, amplification and expression in diffuse large B-cell 
      lymphoma.
PG  - 480-5
LID - 10.1111/j.1600-0609.2011.01684.x [doi]
AB  - AIMS: Aim of the study is to investigate diffuse large B-cell lymphoma (DLBCL) 
      for the presence of BCL3 gene rearrangement and protein expression and to 
      correlate these with immunophenotypic subsets of DLBCL. We aimed to investigate 
      the pathogenetic implication of BCL3 in DLBCL. METHODS AND RESULTS: Tissue 
      microarray sections from 78 DLBCLs were evaluated for BCL3 protein expression 
      using immunohistochemistry and for BCL3 and IGH rearrangement using Fluorescent 
      in situ hybridisation (FISH) with split-apart probes. BCL3 expression was 
      positive in 36/78 cases, of which BCL3 rearrangement was seen seen in one case. 
      Three additional cases showed evidence of trisomy of BCL3/chromosome 19, and two 
      of these three cases showed BCL3 expression. The four cases with FISH-detectable 
      abnormalities showed MUM1 expression and had a non-germinal center (GC) 
      phenotype. The median [and inter-quartile range (IQR)] percentage of 
      BCL3-positive cells in MUM1-positive and MUM1-negative subsets was 65% (5-85%) 
      and 5% (0-20%), respectively (P < 0.001). The median (IQR) percentage of 
      BCL3-positive cells among GC and non-GC subsets of DLBCLs was 12% (12-81%) and 
      60% (6-87%), respectively (P = 0.022). CONCLUSION: Rearrangement or amplification 
      involving the BCL3 gene is a rare event in DLBCL but is likely to play a role in 
      the pathogenesis of a minority of de novo DLBCL. BCL3 over-expression is more 
      frequent and occurs in the absence of rearrangement or amplification and is a 
      feature of the non-GC subset of DLBCL.
CI  - (c) 2011 John Wiley & Sons A/S.
FAU - Ibrahim, Hazem A H
AU  - Ibrahim HA
AD  - Department of Histopathology, Hammersmith Hospital and Imperial College, London, 
      UK.
FAU - Amen, Furrat
AU  - Amen F
FAU - Reid, Alistair G
AU  - Reid AG
FAU - Naresh, Kikkeri N
AU  - Naresh KN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110819
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (B-Cell Lymphoma 3 Protein)
RN  - 0 (BCL3 protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Aged
MH  - B-Cell Lymphoma 3 Protein
MH  - Female
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/*genetics
MH  - Male
MH  - Middle Aged
MH  - Proto-Oncogene Proteins/*genetics
MH  - Transcription Factors/*genetics
EDAT- 2011/07/15 06:00
MHDA- 2011/12/28 06:00
CRDT- 2011/07/15 06:00
PHST- 2011/07/15 06:00 [entrez]
PHST- 2011/07/15 06:00 [pubmed]
PHST- 2011/12/28 06:00 [medline]
AID - 10.1111/j.1600-0609.2011.01684.x [doi]
PST - ppublish
SO  - Eur J Haematol. 2011 Dec;87(6):480-5. doi: 10.1111/j.1600-0609.2011.01684.x. Epub 
      2011 Aug 19.